AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio (updated)

ImmunoGen

30/11/2023 12:41

(Adds details throughout)
       Nov 30 (Reuters) - AbbVie  ABBV.N  said on Thursday it
will buy drugmaker ImmunoGen  IMGN.O  for $10.1 billion,
boosting its presence in the market for cancer treatments.
    The drugmaker will pay $31.26 per ImmunoGen share in cash,
representing a premium of 94.6% to the last closing price. 
    This transaction is expected to close in the middle of 2024,
AbbVie said. 

 (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini
Ganguli)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))